-
Physicians Likely To Support Portola's Betrixaban
Tuesday, December 27, 2016 - 1:07pm | 250Read More...Morgan Stanley is bullish on Portola Pharmaceuticals Inc (NASDAQ: PTLA) following the FDA acceptance of betrixaban for priority review. With priority review, betrixaban will receive an accelerated assessment of six months with a PDUFA date of June 24, 2017. Betrixaban is an oral, once-daily Factor...
-
Goldman Downgrades Portola Pharma To Neutral, Removes From Buy List
Monday, March 28, 2016 - 9:35am | 299Read More...Goldman Sachs’ Jay Olson downgraded the rating on Portola Pharmaceuticals Inc (NASDAQ: PTLA) from Buy to Neutral, while reducing the price target from $65 to $30. APEX Study Miss Removing the stock from Goldman Sachs’ America's Buy List, Olson mentioned that the topline results show...
